[go: up one dir, main page]

MX2007011039A - Sistema de solvente para aumentar la solubilidad de agentes farmaceuticos. - Google Patents

Sistema de solvente para aumentar la solubilidad de agentes farmaceuticos.

Info

Publication number
MX2007011039A
MX2007011039A MX2007011039A MX2007011039A MX2007011039A MX 2007011039 A MX2007011039 A MX 2007011039A MX 2007011039 A MX2007011039 A MX 2007011039A MX 2007011039 A MX2007011039 A MX 2007011039A MX 2007011039 A MX2007011039 A MX 2007011039A
Authority
MX
Mexico
Prior art keywords
solubility
increase
salt
polyethylene glycol
solvent system
Prior art date
Application number
MX2007011039A
Other languages
English (en)
Inventor
Nachiappan Chidambaram
Aqeel Fatmi
Original Assignee
Banner Pharmacaps Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36581722&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2007011039(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Banner Pharmacaps Inc filed Critical Banner Pharmacaps Inc
Publication of MX2007011039A publication Critical patent/MX2007011039A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describen en la presente composiciones farmaceuticas liquidas y semi-solidas, que se pueden administrar en forma liquida o se pueden utilizar para preparar capsulas. La composicion comprende la sal de uno o mas agentes activos, polietilenglicol, 0.2-1.0 equivalentes en mol de un agente desionizante por mol de agente activo y agua. El pH de la composicion se ajusta dentro del intervalo de 2.5 - 7.5. El agente desionizante causa desionizacion parcial (neutralizacion) de la sal del agente activo dando por resultado biodisponibilidad aumentada de sales de agentes activos debilmente acidicos, basicos o anfotericos asi como cantidades menores de esteres de polietilenglicol (PEG).
MX2007011039A 2005-03-08 2006-03-06 Sistema de solvente para aumentar la solubilidad de agentes farmaceuticos. MX2007011039A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65967905P 2005-03-08 2005-03-08
PCT/US2006/007788 WO2006096580A1 (en) 2005-03-08 2006-03-06 Solvent system for enhancing the solubility of pharmaceutical agents

Publications (1)

Publication Number Publication Date
MX2007011039A true MX2007011039A (es) 2008-03-07

Family

ID=36581722

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007011039A MX2007011039A (es) 2005-03-08 2006-03-06 Sistema de solvente para aumentar la solubilidad de agentes farmaceuticos.

Country Status (14)

Country Link
US (8) US20070053868A1 (es)
EP (2) EP3061447A1 (es)
CN (2) CN101166520B (es)
CA (1) CA2600023C (es)
CY (1) CY1118321T1 (es)
DK (1) DK1863458T4 (es)
ES (1) ES2606767T5 (es)
HU (1) HUE030784T2 (es)
LT (1) LT1863458T (es)
MX (1) MX2007011039A (es)
PL (1) PL1863458T5 (es)
PT (1) PT1863458T (es)
SI (1) SI1863458T2 (es)
WO (1) WO2006096580A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070053868A1 (en) 2005-03-08 2007-03-08 Banner Pharmacaps, Inc. Solvent system for enhancing the solubility of pharmaceutical agents
WO2008070950A1 (en) * 2006-12-13 2008-06-19 Laboratoires Mauves Inc. Pharmaceutical solution formulations for encapsulation into gelatin capsules or other dosage forms
US20090104236A1 (en) * 2007-10-18 2009-04-23 Pharmaceutics International, Inc. Pharmaceutical solid hybrids
US8236786B2 (en) 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
US20110052679A1 (en) * 2009-08-25 2011-03-03 Pharmaceutics International, Inc. Solid naproxen concentrates and related dosage forms
CA2690488C (en) * 2010-01-19 2013-06-11 Accucaps Industries Limited Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof
MX347373B (es) * 2011-08-04 2017-04-25 Omeros Corp Soluciones anti-inflamatorias estables para inyección.
CN103239711B (zh) * 2013-05-24 2015-08-05 成都天台山制药有限公司 曲普瑞林注射液和制法
WO2015157138A1 (en) 2014-04-07 2015-10-15 Banner Life Sciences Llc Abuse-deterrent controlled release formulations
US10772842B2 (en) 2015-01-09 2020-09-15 Patheon Softgels Inc. Abuse-deterrent opioids
CN104083339A (zh) * 2014-08-04 2014-10-08 人福普克药业（武汉）有限公司 萘普生钠软胶囊及其制备方法
US20160243044A1 (en) * 2015-02-20 2016-08-25 Enspire Group LLC Soft gelatin capsules containing fexofenadine
CA2978269A1 (en) * 2015-03-02 2016-09-09 Bionpharma Healthcare Llc Immediate release soluble ibuprofen compositions
US10182993B2 (en) 2015-04-06 2019-01-22 Patheon Softgels Inc. Compositions for colonic delivery of drugs
TWI620577B (zh) * 2016-11-23 2018-04-11 乙醯胺酚及曲馬多共溶複方止痛口服液
WO2020081649A1 (en) 2018-10-16 2020-04-23 Bayer Healthcare Llc Softgels with solid or gel-like polymeric fill matrix
US20220202751A1 (en) * 2019-04-26 2022-06-30 R.P. Scherer Technologies, Llc Mini softgel naproxen composition
CR20230376A (es) * 2021-01-11 2023-12-12 Bayer HealthCare LLC Formulaciones de gel líquido concentradas que contienen sales de naproxeno

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3035973A (en) 1958-08-01 1962-05-22 Lloyd Brothers Inc Gelatin capsule containing calcium dioctyl sulfosuccinate
US5071643A (en) 1986-10-17 1991-12-10 R. P. Scherer Corporation Solvent system enhancing the solubility of pharmaceuticals for encapsulation
US5141961A (en) 1991-06-27 1992-08-25 Richrdson-Vicks Inc. Process for solubilizing difficulty soluble pharmaceutical actives
JP3121080B2 (ja) * 1991-12-19 2000-12-25 アール・ピー・シーラー コーポレイション カプセル封入用溶液
US5505961A (en) 1993-08-05 1996-04-09 R. P. Scherer Corporation Gelatin capsules containing a highly concentrated acetaminophen solution
US5478858A (en) * 1993-12-17 1995-12-26 The Procter & Gamble Company 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists
US5484606A (en) * 1994-01-24 1996-01-16 The Procter & Gamble Company Process for reducing the precipitation of difficulty soluble pharmaceutical actives
US5484608A (en) * 1994-03-28 1996-01-16 Pharmavene, Inc. Sustained-release drug delivery system
WO1995031979A1 (en) * 1994-05-19 1995-11-30 R.P. Scherer International Corporation Solutions of aryl or heteroaryl substituted alkanoic acids in lipophilic solvents and soft gelatin capsules containing such solutions
US5641512A (en) 1995-03-29 1997-06-24 The Procter & Gamble Company Soft gelatin capsule compositions
US5648358A (en) * 1996-03-05 1997-07-15 Mitra; Sekhar Compositions and methods for treating respiratory disorders
US5843469A (en) * 1997-04-11 1998-12-01 Mcentee; William J. Lipid soluble forms of thiamine for prevention and treatment of age-related cognitive impairment of the nervous system
US6066339A (en) 1997-10-17 2000-05-23 Elan Corporation, Plc Oral morphine multiparticulate formulation
WO1999036060A1 (en) 1998-01-20 1999-07-22 Applied Analytical Industries, Inc. Oral liquid compositions
US6365180B1 (en) 1998-01-20 2002-04-02 Glenn A. Meyer Oral liquid compositions
US6183779B1 (en) * 1999-03-22 2001-02-06 Pharmascience Inc. Stabilized pharmaceutical composition of a nonsteroidal anti-inflammatory agent and a prostaglandin
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6383515B2 (en) * 1999-05-28 2002-05-07 Sawyer Maryjean Solvent system for enhancing solubility
US6251426B1 (en) 1999-09-02 2001-06-26 Banner Pharmacaps, Inc. Ibuprofen-containing softgels
US20030216423A1 (en) * 2000-05-24 2003-11-20 Sergio Ulloa Stable liquid and solid formulations
US20020022058A1 (en) * 2000-07-08 2002-02-21 Lovercheck Dale R. Unit dose of material in system and method
US6387400B1 (en) 2000-08-29 2002-05-14 R.P. Scherer Technologies, Inc. Process for preparing pharmaceutical compositions for use with soft gelatin formulations
US7101572B2 (en) 2001-12-07 2006-09-05 Unilab Pharmatech, Ltd. Taste masked aqueous liquid pharmaceutical composition
US6689382B2 (en) 2002-05-15 2004-02-10 Procaps S.A. Soft shell gelatin capsules containing non-steroidal anti-inflammatories
AU2003301121A1 (en) 2002-12-18 2004-07-14 Pain Therapeutics, Inc. Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
AU2003261633A1 (en) * 2003-02-12 2004-09-06 R And P Korea Co., Ltd. Solvent system of hardly soluble drug with improved elution rate
US20050158377A1 (en) * 2004-01-20 2005-07-21 Popp Karl F. Dermatologic soft gel compositions
US8231896B2 (en) * 2004-11-08 2012-07-31 R.P. Scherer Technologies, Llc Non-gelatin soft capsule system
US20070053868A1 (en) 2005-03-08 2007-03-08 Banner Pharmacaps, Inc. Solvent system for enhancing the solubility of pharmaceutical agents

Also Published As

Publication number Publication date
US20160263063A1 (en) 2016-09-15
CN101166520A (zh) 2008-04-23
SI1863458T1 (sl) 2017-01-31
CN101166520B (zh) 2013-01-09
DK1863458T4 (da) 2022-04-04
HUE030784T2 (en) 2017-06-28
US20180296512A1 (en) 2018-10-18
PL1863458T3 (pl) 2017-03-31
US9693978B2 (en) 2017-07-04
US20160106841A1 (en) 2016-04-21
US20210338616A1 (en) 2021-11-04
US10022344B2 (en) 2018-07-17
ES2606767T3 (es) 2017-03-27
PT1863458T (pt) 2016-12-20
CN102940887B (zh) 2015-12-23
EP1863458B1 (en) 2016-09-14
US10028925B2 (en) 2018-07-24
US20180071236A1 (en) 2018-03-15
EP1863458B2 (en) 2022-03-02
US11090280B2 (en) 2021-08-17
DK1863458T3 (da) 2017-01-02
CN102940887A (zh) 2013-02-27
US20070053868A1 (en) 2007-03-08
SI1863458T2 (sl) 2022-05-31
US9693979B2 (en) 2017-07-04
US20170296495A1 (en) 2017-10-19
EP3061447A1 (en) 2016-08-31
CY1118321T1 (el) 2017-06-28
EP1863458A1 (en) 2007-12-12
CA2600023C (en) 2011-11-01
ES2606767T5 (es) 2022-05-06
LT1863458T (lt) 2016-12-12
PL1863458T5 (pl) 2023-01-02
US20240342123A1 (en) 2024-10-17
CA2600023A1 (en) 2006-09-14
WO2006096580A1 (en) 2006-09-14

Similar Documents

Publication Publication Date Title
MX2007011039A (es) Sistema de solvente para aumentar la solubilidad de agentes farmaceuticos.
ES2536206T3 (es) Parche medicinal
ES2524320T3 (es) Composición para la prevención o el tratamiento de enfermedad asociada con trombo o émbolo
ES2539861T3 (es) Formulaciones en emulsión de clevidipina que contienen agentes antimicrobianos
PE20071310A1 (es) Formulaciones liquidas de fenilefrina
PE20141539A1 (es) Una nueva composicion terapeutica que contiene apomorfina como principio activo
EA201170543A1 (ru) Жидкий фармацевтический состав, содержащий парацетамол
FI4374878T3 (fi) Karbetosiinia käsittävä farmaseuttinen koostumus
BR112015025172A2 (pt) composição farmacêutica
CL2009002073A1 (es) Composicion farmaceutica solida para la liberacion controlada de un agente activo activo en el tracto gastrointestinal que comprende al menos un agente acido con solubilidad de menos de 0,3 mg/ml en solucion acuosa a un ph alrededor del pka del agente acido, un polimero hidrofilo, un alcanizador; uso en trastornos cardiovasculares.
AR081364A1 (es) Composiciones farmaceuticas de pazopanib y metodos para su elaboracion
CY1108700T1 (el) Συνθεσεις απελευθερωσης φαρμακου εστερα αλφα-υδροξυ οξεος και μεθοδοι χρησης
AR053737A1 (es) Formulacion pediatrica de topiramato
AR041021A1 (es) Composicion topica
ES2720954T3 (es) Formulaciones estabilizadas de estatina
MX2009004439A (es) Composicion de ibuprofeno.
CO6220902A2 (es) Formulacion en polvo del valganciclovir
AR077155A1 (es) Nanodispersion, nanoparticulas y solucion
CL2010001642A1 (es) Composicion farmaceutica topica en gel que comprende a) 0,25 a 4,5% de un agente activo para el tratamiento de la queratosis actinica, b) un agente queratoliticamente activo, c) un formador de gel, d) un solvente organico, y menos de 5% en peso de agua; util para el tratamiento de la queratosis actinica.
AR072359A1 (es) Encapsulacion de agentes biologicamente activos
CL2008001605A1 (es) Una formulacion de dosis intranasal que comprende asenapina o una sal farmaceuticamente aceptable y un portador liquido que contiene agua y un poliol, util para el tratamiento de la esquizofrenia.
AR081520A1 (es) Composicion farmaceutica que comprende una dispersion solida de tacrolimus en un vehiculo
AR092840A1 (es) Elaboracion de degarelix
AR093297A1 (es) Formulacion liquida que comprende un compuesto neutralizante de gm-csf
ES2531241T3 (es) Composición farmacéutica líquida estable a base de trazodona

Legal Events

Date Code Title Description
FG Grant or registration
PD Change of proprietorship

Owner name: BANNER LIFE SCIENCES, LLC